Evidence map›Paper›PMID 30837526›Full record

ArticleScientific reports2019

Microarray assessment of N-glycan-specific IgE and IgG profiles associated with Schistosoma mansoni infection in rural and urban Uganda.

Gyaviira Nkurunungi, Angela van Diepen, Jacent Nassuuna, Richard E Sanya, Margaret Nampijja, Irene Nambuya, Joyce Kabagenyi, Sonia Serna, Niels-Christian Reichardt, Ronald van Ree and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Serum antibody screening using glycan arrays.Chemical Society reviews · 2024
    Review
  5. Anti-schistosomal immunity to core xylose/fucose in N-glycans.Frontiers in molecular biosciences · 2023
    Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Gyaviira NkurunungiImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda. gyaviira.nkurunungi@mrcuganda.org.ORCID 0000-0003-4062-9105
Angela van DiepenDepartment of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
Jacent NassuunaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda.
Richard E SanyaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda.
Margaret NampijjaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda.
Irene NambuyaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda.
Joyce KabagenyiImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda.
Sonia SernaGlycotechnology Laboratory, Centro de Investigación Cooperativa en Biomateriales (CIC biomaGUNE), San Sebastián, Spain.
Niels-Christian ReichardtGlycotechnology Laboratory, Centro de Investigación Cooperativa en Biomateriales (CIC biomaGUNE), San Sebastián, Spain.
Ronald van ReeAmsterdam University Medical Centers, Departments of Experimental Immunology and of Otorhinolaryngology, Amsterdam, The Netherlands.
Emily L WebbMRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Alison M ElliottImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, Uganda.ORCID 0000-0003-2818-9549
Maria YazdanbakhshDepartment of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-7666-1441
Cornelis H HokkeDepartment of Parasitology, Leiden University Medical Center, Leiden, The Netherlands. C.H.Hokke@lumc.nl.ORCID 0000-0003-3545-7804
Uganda Virus Research Institute · UGLeiden University Medical Center · NLLondon School of Hygiene & Tropical Medicine · GBCIC biomaGUNE · ESAmsterdam University Medical Centers · NLMakerere University · UG

Funding

Medical Research Council MC_UU_00027/5Medical Research Council MR/K012126/1Medical Research Council MR/R010161/1Wellcome TrustWellcome Trust 095778Wellcome Trust 107743
6 · The paper itself

Abstract

Core β-1,2-xylose and α-1,3-fucose are antigenic motifs on schistosome N-glycans, as well as prominent IgE targets on some plant and insect glycoproteins. To map the association of schistosome infection with responses to these motifs, we assessed plasma IgE and IgG reactivity using microarray technology among Ugandans from rural Schistosoma mansoni (Sm)-endemic islands (n = 209), and from proximate urban communities with lower Sm exposure (n = 62). IgE and IgG responses to core β-1,2-xylose and α-1,3-fucose modified N-glycans were higher in rural versus urban participants. Among rural participants, IgE and IgG to core β-1,2-xylose were positively associated with Sm infection and concentration peaks coincided with the infection intensity peak in early adolescence. Responses to core α-1,3-fucose were elevated regardless of Sm infection status and peaked before the infection peak. Among urban participants, Sm infection intensity was predominantly light and positively associated with responses to both motifs. Principal component and hierarchical cluster analysis reduced the data to a set of variables that captured core β-1,2-xylose- and α-1,3-fucose-specific responses, and confirmed associations with Sm and the rural environment. Responses to core β-1,2-xylose and α-1,3-fucose have distinctive relationships with Sm infection and intensity that should further be explored for associations with protective immunity, and cross-reactivity with other exposures.

Indexed as

AdolescentAdultAnimalsChildChild, PreschoolFemaleGlycosylationHumansImmunoglobulin EImmunoglobulin GMaleMicroarray AnalysisPolysaccharidesPrincipal Component AnalysisRural PopulationSchistosoma mansoniImmunoglobulin EImmunoglobulin GPolysaccharides

Identifiers

PMID30837526
PMCPMC6401159
OpenAlexW2919111059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.